ScholarIQanswers from OpenAlex

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions

PaperCitations, authors & open-access status

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions have?

ScholarIQcitation count

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions has 96 citations in the OpenAlex counts ScholarIQ stores.

When was Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions published?

ScholarIQyear

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions has 2022 year in the ScholarIQ index.

What is the open-access status of Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions?

ScholarIQoa status

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions has hybrid oa status in the ScholarIQ index.

What is the DOI of Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions?

ScholarIQdoi

The DOI for Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions is on the source record.

What is the PMID of Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions?

ScholarIQpmid

The PMID for Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions is on the source record.

What is the OpenAlex record for Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions?

ScholarIQopenalex

The OpenAlex for Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial